Caris Life Sciences Leverages Multimodal Clinical Genomic Dataset and AI to Lead Precision Oncology Following $168M Funding and Nasdaq IPO

Caris Life Sciences, founded in 2008 as the former Molecular Profiling Institute, is headquartered in Irving, Texas, USA. It is a next-generation AI TechBio company and precision medicine service provider centered on patients. The company focuses on developing and commercializing innovative solutions to transform healthcare through integrated molecular information and artificial intelligence/machine learning algorithms. Caris' comprehensive molecular profiling technology is driving a medical revolution, guiding personalized diagnosis and treatment for patients.

Precision medicine aims to provide personalized diagnosis and treatment plans based on individual patients' genetic characteristics, molecular markers, and other information, thereby improving treatment outcomes, reducing medical costs, and enhancing patients' quality of life. Since its establishment, the company has been committed to leveraging advanced technologies to promote the development of precision medicine, continuously focusing on precision medicine in oncology, and has already helped more than 500,000 cancer patients worldwide.In addition to oncology, precision medicine approaches are applicable across a wide range of disease areas, including cardiology, neurology, metabolic disorders, and other chronic conditions.

The Development History of Caris

In the early stages of the company's development, Caris focused on building a foundational technology platform, integrating technologies such as whole exome sequencing, transcriptome sequencing, and protein analysis, laying a solid technical foundation for subsequent business expansion. Its technology platform is capable of conducting comprehensive and in-depth molecular testing on patients' biological samples, obtaining rich genetic information, providing critical data support for precision medicine.

As technology continues to mature and market demand grows, Caris Life Sciences has gradually expanded its business scope. In 2019, the company acquired Pharmatech. By integrating its proprietary molecular profiling technology with Pharmatech's Just-In-Time (JIT) clinical trial platform, Caris redefined the process for pharmaceutical and biotechnology companies to identify and rapidly recruit patients for precision oncology trials, establishing the Caris Pharmatech division. This division aims to optimize the drug development clinical trial process by leveraging its extensive network of 420 research sites in the JIT Oncology Network. Through the integration of resources and strengths from both entities, Caris can more efficiently connect biopharmaceutical researchers with clinical trial participants, accelerating the drug development process and bringing new treatment hopes to more patients.

Caris Life Sciences also secured multiple large-scale financings. In May 2021, the company raised up to $830 million, becoming one of the largest financing deals in the global healthcare industry that year. This brought its total financing to over $1 billion.

Caris Life Sciences Focuses on Developing Next-Generation Precision Digital Healthcare Solutions for the Entire Process of Diagnosis and Treatment of a Wide Range of Diseases. The Core Advantage of the Caris Platform Lies in the Depth, Breadth, and Scale of Data, as Well as Its Vertical and Horizontal Integration Capabilities Within the Business, Driving Innovation.

Caris' multi-omics technology platform is composed of five pillars:

(1) Caris Assure

(2) Molecular Profiling (MI Profile)

(3) Caris Discovery

(4) Caris Strategic Data

(5) Caris Infrastructure

These five pillars work together to form a virtuous cycle, establishing a comprehensive analytical approach that will drive the growing demand for genomic analysis capabilities, expand clinical genomic datasets, inform optimized solutions, and ultimately improve patient outcomes.

The Five-in-One of Caris Platform

(1) Caris Assure is a blood-based universal whole exome sequencing/whole transcriptome sequencing (WES/WTS) analysis solution designed to span the entire process of cancer treatment, including multi-cancer early detection (MCED), minimal residual disease (MRD) tracking, treatment selection, and treatment monitoring. Each clinical case can generate over 42 billion data points, covering 168,000 molecular markers. With extensive experience and data accumulation in MI analysis testing (MI Profile), Caris has developed the Caris Assure test, enabling a deep understanding of the origin of a patient’s disease, identifying which therapies a tumor may be sensitive to, gaining insights into how tumors evolve to resist treatment, and exploring the best ways to control or cure the disease.

Caris Assure Blood-Based Analysis Solution

(2) MI Profile is an analytical solution launched by Caris that uses tissue as the test sample to assist doctors in selecting treatment options. It covers comprehensive WES/WTS analysis testing, as well as immunohistochemistry (IHC) protein expression testing. Caris employs integrated molecular profiling technology through WES/WTS to test each eligible patient sample and generate billions of data points, revealing a personalized molecular blueprint of the patient's disease. Among this, MI Cancer Seek, as part of MI Profile, provides a coverage depth of up to 1500x for clinically relevant DNA genes, with the remaining exons covered at 300x to 400x; Caris Assure delivers an average raw sequencing depth of 8000x for clinically relevant genes, surpassing most testing methods available on the market.

（3）Caris Discovery combines Caris' data with artificial intelligence, enabling it to discover previously unknown drug targets and apply them to the development of various types of drugs.Given that Caris can detect genetic mutations, insertions, and deletions through Whole Exome Sequencing (WES), and evaluate gene expression and detect fusions in each patient's tumor via Whole Transcriptome Sequencing (WTS), Caris Discovery has a significant advantage in discovering neoantigens, which can facilitate the development of personalized therapies.

(4) Caris Strategic Data: Caris has built one of the largest and most comprehensive multimodal clinical genomic datasets in the field of oncology, including genomic data, clinical data, digital slide images, and tissue data. Next-generation sequencing (NGS) methods such as WES/WTS can generate vast amounts of genomic data, while artificial intelligence (AI) and machine learning (ML) can be used to mine this data, address complex biological questions, and propel precision medicine into mainstream clinical treatment.

As of December 31, 2024, Caris has conducted more than 6.5 million tests, measuring over 38 billion molecular markers from more than 1.3 quadrillion data points.To analyze the accumulated data, Caris utilizes a variety of artificial intelligence and AI/ML tools in clinical testing, R&D, and biopharmaceutical operations., including more than 50 clinical sequencing automation and variant recognition AI, over 100 RNA expression AI features, approximately 20 multi-omics AI/ML treatment response prediction models, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/machine learning classifiers, and 12 AI/machine learning support tools.

To further enhance the applicability and practicality of multimodal datasets for biopharmaceutical companies, Caris has also reached agreements with clinical data partners such as ConcertAI, Flatiron, and COTA to jointly create matched clinical-genomic datasets that biopharmaceutical companies can license for drug development.Currently, Caris has reached agreements with companies such as AbbVie and Moderna to authorize the use of these datasets to aid in drug development.Caris uses these datasets to create many of its algorithms and features, with the breadth and depth of its data assets forming a significant competitive barrier for Caris.

Caris Platform Effectively Integrates Sequencing Capabilities, AI/ML Technologies, and Cloud Computing Power

However, the application of AI in the field of cancer still faces challenges, especially in generating accurate and extensive molecular information to support algorithms. The accuracy of AI/ML algorithm predictions depends on the accuracy and breadth of the foundational data used for training and application, and the accuracy of NGS genomic data is closely related to the coverage depth of sample sequencing.

Moreover, the research capability of AI also depends on the number of genes being tested. Complex diseases often involve various genomic alterations, and cancers that are more aggressive with poorer prognoses tend to have more genomic changes. Therefore, it is necessary to test a large number of genes and incorporate them into datasets for accurate research. Cloud computing architecture provides the feasibility for this, not only enabling large-scale scalability and real-time cross-industry collaboration but also offering opportunities for efficient storage, processing, and analysis of massive amounts of data.

(5) Caris Infrastructure includes comprehensive laboratories, R&D, and sales infrastructure, which form the foundation of Caris' business. Operational capabilities: Caris possesses strong testing capabilities, including facilities distributed across four precision medicine laboratories covering more than 275,000 square feet, as well as 50 NovaSeq sequencing systems, with a daily throughput of over 1 trillion reads, providing sufficient capacity to meet current operations and future growth demands.

Caris also has dedicated R&D infrastructure, including a specialized laboratory and more than 200 R&D employees. In addition to internal research, Caris frequently collaborates with external academic centers and researchers, such as the establishment of the Caris Precision Oncology Alliance (Caris POA) in 2015, a growing global network of cancer centers and research alliances that supports research partner engagement, identifies collaboration opportunities, and advances precision oncology research. As of December 31, 2024, the Caris POA has 96 members, and the total number of members has quadrupled since 2017.

To support Caris' sales activities and business expansion, as of December 31, 2024, Caris has built a highly targeted sales team in the United States with over 275 members. Additionally, there are more than 50 well-trained Molecular Science Liaisons (MSLs) who hold either a Ph.D. or an M.D. These MSLs focus on providing training to physicians and healthcare providers.

02 Business Model and Market Performance

Caris Life Sciences’ business mainly focuses on precision medicine solutions, with an initial emphasis on the field of oncology, serving clinical, academic, and biopharmaceutical markets, specifically including the following aspects:

• Genomic Profiling Services: The company provides precision oncology solutions to physicians who order MI Profile and Caris Assure, recognizing revenue upon delivering the results of such profiling services to the ordering physicians.

• Pharmaceutical R&D Services: Utilizing the Caris platform to provide R&D services for biopharmaceutical partners, including various service contracts such as genomic analysis solutions, development services, and strategic data services, with revenue recognized based on the completion of performance obligations.

Caris' Business Model

From the financial data, the company's revenue shows a growth trend. In 2023, the company's total revenue was $306 million, of which genetic analysis services revenue was $279 million, and pharmaceutical R&D services revenue was $27.38 million. In 2024, both genetic analysis services revenue and pharmaceutical R&D services revenue increased. For instance, the growth in genetic analysis services revenue was driven by an increase in clinical cases using MI Profile and Caris Assure for treatment selection. However, the company is still in a loss-making state, with a net loss of $341 million in 2023. Despite business growth in 2024, profitability has not yet been achieved, mainly due to expenditures on R&D, marketing, and operational costs.

Increase in Clinical Cases and Revenue Growth at Caris

In the precision medicine market, Caris also faces fierce competition, with main rivals including Foundation Medicine, Guardant Health, and other companies. The industry is highly competitive with rapid technological iteration, requiring companies to continuously innovate to maintain their competitiveness.

• Foundation Medicine: A precision medicine service provider focused on cancer genomics research and clinical applications. Foundation Medicine possesses advanced gene sequencing technology and extensive clinical experience, with its products and services being widely used on a global scale. Compared to Caris Life Sciences, Foundation Medicine conducts more in-depth research in the field of cancer genomics and maintains closer collaborations with pharmaceutical companies.

• Guardant Health: A provider of liquid biopsy technology, whose liquid biopsy products have significant advantages in early cancer detection and monitoring. The company's liquid biopsy technology is characterized by fast detection speed, high accuracy, and low cost, with a relatively high market share. Compared to Caris, Guardant Health has a more mature commercial application of liquid biopsy technology.

From the market opportunity perspective, Caris Life Sciences is expected to cover multiple areas including early detection, treatment selection, MRD tracking and treatment monitoring, core biopharmaceutical services, and biopharmaceutical data services. Additionally, its platform holds significant market potential in other chronic disease fields beyond oncology.

In terms of pipeline layout, the company has built up a certain product matrix, and some projects are proceeding rapidly. As technology continues to mature and the market gradually expands, the company is expected to make greater breakthroughs in the field of precision medicine. The application of Caris Assure in areas such as early detection of multiple cancers, if successful, will greatly improve the early diagnosis rate and treatment outcomes of cancer.

Caris' Market Landscape in the Field of Precision Oncology

Author: Zhancai Hou, Changjian Huang

Share

Like

Like